According to a research report published earlier this morning, Goldman Sachs has upgraded Biogen Idec BIIB from Neutral to Buy, and has increased PT from $120 to $150.
In the report, Goldman Sachs commented, “Despite the significant outperformance (up 77% vs. 6% for S&P LTM), we see the risk/reward as attractive. We see the success of BG-12 supporting the current valuation, with multiple optionalities for upside that are underestimated in Street estimates: (1) a reasonable probability of success of dexpramipexole (dex) in ALS, a $1.5bn+ opportunity; (2) long acting hemophilia products could potentially capture 10%-20% of the market, a $1bn+ opportunity; and (3) Gilenya safety issues could expand BG-12's and Tysabri's potential.”
Biogen Idec closed yesterday at $128.80.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in